[Form 4] Travere Therapeutics, Inc. Insider Trading Activity
Christopher R. Cline, Chief Financial Officer of Travere Therapeutics, sold 470 shares of the company's common stock on 08/27/2025 at a price of $17.31 per share under a written plan intended to satisfy Rule 10b5-1(c). The filing reports 92,656 shares beneficially owned by Mr. Cline after the transaction.
The sale was executed pursuant to a 10b5-1 plan adopted on May 28, 2025 and included additional shares sold to cover the tax obligation arising from the vesting of performance-based restricted stock units that vested in May 2025. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 08/28/2025.
Christopher R. Cline, Chief Financial Officer di Travere Therapeutics, ha venduto 470 azioni delle azioni ordinarie della societ脿 il 27/08/2025 al prezzo di $17.31 per azione nell'ambito di un piano scritto volto a soddisfare la Regola 10b5-1(c). La comunicazione riporta che dopo la transazione il Sig. Cline detiene beneficiariamente 92.656 azioni.
La vendita 猫 stata eseguita ai sensi di un piano 10b5-1 adottato il 28/05/2025 e comprendeva azioni aggiuntive vendute per coprire l'imposta derivante dalla maturazione di unit脿 azionarie vincolate basate sulla performance che sono maturate a maggio 2025. Il Modulo 4 猫 stato firmato per conto del soggetto segnalante da un procuratore il 28/08/2025.
Christopher R. Cline, Director Financiero de Travere Therapeutics, vendi贸 470 acciones de las acciones comunes de la compa帽铆a el 27/08/2025 a un precio de $17.31 por acci贸n bajo un plan escrito destinado a cumplir la Regla 10b5-1(c). El informe indica que tras la transacci贸n el Sr. Cline posee a t铆tulo beneficiario 92.656 acciones.
La venta se ejecut贸 conforme a un plan 10b5-1 adoptado el 28/05/2025 e incluy贸 acciones adicionales vendidas para cubrir la obligaci贸n tributaria derivada de la consolidaci贸n de unidades restringidas basadas en rendimiento que vencieron en mayo de 2025. El Formulario 4 fue firmado en nombre de la persona informante por un apoderado el 28/08/2025.
Christopher R. Cline, Travere Therapeutics鞚� 斓滉碃鞛毂呾瀯鞛�(CFO)電� 2025-08-27鞐� 須岇偓 氤错喌欤� 470欤�毳� 欤茧嫻 $17.31鞐� 毵る弰頄堨溂氅�, 鞚措姅 Rule 10b5-1(c)毳� 於╈”頃橁赴 鞙勴暣 鞛戩劚霅� 瓿勴殟鞐� 霐半ジ 瓴冹瀰雼堧嫟. 頃措嫻 鞁犼碃靹滌棎電� 瓯半灅 頉� Cline 鞌皜 92,656欤�毳� 鞁れ澋 氤挫湢頃橁碃 鞛堧姅 瓴冹溂搿� 氤搓碃霅橃柎 鞛堨姷雼堧嫟.
鞚� 毵る弰電� 2025-05-28鞐� 毂勴儩霅� 10b5-1 瓿勴殟鞐� 霐半澕 鞁ろ枆霅橃棃鞙茧┌, 2025雲� 5鞗旍棎 靹标臣 旮半皹 鞝滍暅欤检嫕 雼渼臧� 頇曥爼霅橂┌ 氚滌儩頃� 靹戈笀 攵�雼挫潉 於╇嫻頃橁赴 鞙勴暣 於旉皜搿� 毵る弰霅� 欤检嫕鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. Form 4電� 2025-08-28鞐� 雽�毽澑(氤�順胳偓雽�毽�)鞐� 鞚橅暣 鞁犼碃鞚胳潉 雽�鞁犿暣 靹滊獏霅橃棃鞀惦媹雼�.
Christopher R. Cline, directeur financier de Travere Therapeutics, a vendu 470 actions des actions ordinaires de la soci茅t茅 le 27/08/2025 au prix de 17,31 $ par action dans le cadre d'un plan 茅crit destin茅 脿 satisfaire la r猫gle 10b5-1(c). Le d茅p么t indique qu'apr猫s la transaction, M. Cline d茅tient b茅n茅fiquement 92 656 actions.
La vente a 茅t茅 ex茅cut茅e conform茅ment 脿 un plan 10b5-1 adopt茅 le 28/05/2025 et comprenait des actions suppl茅mentaires vendues pour couvrir l'obligation fiscale r茅sultant de l'acquisition de unit茅s d'actions restreintes fond茅es sur la performance qui ont acquis droit en mai 2025. Le formulaire 4 a 茅t茅 sign茅 au nom de la personne d茅clarante par un mandataire le 28/08/2025.
Christopher R. Cline, Chief Financial Officer von Travere Therapeutics, verkaufte am 27.08.2025 470 Aktien der Stammaktien des Unternehmens zum Preis von $17.31 je Aktie im Rahmen eines schriftlichen Plans zur Erf眉llung der Regel 10b5-1(c). Die Einreichung berichtet, dass Herr Cline nach der Transaktion wirtschaftlich 92.656 Aktien besitzt.
Der Verkauf erfolgte gem盲脽 einem am 28.05.2025 angenommenen 10b5-1-Plan und beinhaltete zus盲tzliche verkaufte Aktien zur Begleichung der Steuerverpflichtung, die durch das Vesting leistungsabh盲ngiger Restricted Stock Units im Mai 2025 entstand. Das Formular 4 wurde am 28.08.2025 im Namen der meldenden Person von einem Bevollm盲chtigten unterzeichnet.
- Transaction executed under a 10b5-1(c) plan, indicating adherence to an established trading policy
- Sale was linked to tax withholding for vested PSUs, suggesting the disposition was compensation-related rather than opportunistic
- None indicated in the filing
Insights
TL;DR: Routine insider sale under a pre-established 10b5-1 plan to cover tax from vested PSUs; governance procedures appear followed.
The Form 4 documents a small, planned disposition of 470 shares at $17.31 each under a 10b5-1(c) trading plan adopted May 28, 2025. The filing explicitly states the sale included additional shares to satisfy tax obligations from PSUs that vested in May 2025, indicating the transaction was not an opportunistic sale but a tax-cover event tied to compensation vesting. The use of a 10b5-1 plan and execution through an attorney-in-fact are consistent with standard governance controls for insider trading.
TL;DR: Transaction is informational and limited in size; it does not on its face indicate a material change in insider ownership.
The reported sale of 470 shares at $17.31 reduced the reporting person鈥檚 direct holdings to 92,656 shares. The document provides exact quantities and price but does not disclose any additional sales or changes to compensation arrangements beyond the PSU vesting note. Based solely on the disclosed figures, this appears to be a routine, non-material insider disposition executed under a pre-existing plan.
Christopher R. Cline, Chief Financial Officer di Travere Therapeutics, ha venduto 470 azioni delle azioni ordinarie della societ脿 il 27/08/2025 al prezzo di $17.31 per azione nell'ambito di un piano scritto volto a soddisfare la Regola 10b5-1(c). La comunicazione riporta che dopo la transazione il Sig. Cline detiene beneficiariamente 92.656 azioni.
La vendita 猫 stata eseguita ai sensi di un piano 10b5-1 adottato il 28/05/2025 e comprendeva azioni aggiuntive vendute per coprire l'imposta derivante dalla maturazione di unit脿 azionarie vincolate basate sulla performance che sono maturate a maggio 2025. Il Modulo 4 猫 stato firmato per conto del soggetto segnalante da un procuratore il 28/08/2025.
Christopher R. Cline, Director Financiero de Travere Therapeutics, vendi贸 470 acciones de las acciones comunes de la compa帽铆a el 27/08/2025 a un precio de $17.31 por acci贸n bajo un plan escrito destinado a cumplir la Regla 10b5-1(c). El informe indica que tras la transacci贸n el Sr. Cline posee a t铆tulo beneficiario 92.656 acciones.
La venta se ejecut贸 conforme a un plan 10b5-1 adoptado el 28/05/2025 e incluy贸 acciones adicionales vendidas para cubrir la obligaci贸n tributaria derivada de la consolidaci贸n de unidades restringidas basadas en rendimiento que vencieron en mayo de 2025. El Formulario 4 fue firmado en nombre de la persona informante por un apoderado el 28/08/2025.
Christopher R. Cline, Travere Therapeutics鞚� 斓滉碃鞛毂呾瀯鞛�(CFO)電� 2025-08-27鞐� 須岇偓 氤错喌欤� 470欤�毳� 欤茧嫻 $17.31鞐� 毵る弰頄堨溂氅�, 鞚措姅 Rule 10b5-1(c)毳� 於╈”頃橁赴 鞙勴暣 鞛戩劚霅� 瓿勴殟鞐� 霐半ジ 瓴冹瀰雼堧嫟. 頃措嫻 鞁犼碃靹滌棎電� 瓯半灅 頉� Cline 鞌皜 92,656欤�毳� 鞁れ澋 氤挫湢頃橁碃 鞛堧姅 瓴冹溂搿� 氤搓碃霅橃柎 鞛堨姷雼堧嫟.
鞚� 毵る弰電� 2025-05-28鞐� 毂勴儩霅� 10b5-1 瓿勴殟鞐� 霐半澕 鞁ろ枆霅橃棃鞙茧┌, 2025雲� 5鞗旍棎 靹标臣 旮半皹 鞝滍暅欤检嫕 雼渼臧� 頇曥爼霅橂┌ 氚滌儩頃� 靹戈笀 攵�雼挫潉 於╇嫻頃橁赴 鞙勴暣 於旉皜搿� 毵る弰霅� 欤检嫕鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. Form 4電� 2025-08-28鞐� 雽�毽澑(氤�順胳偓雽�毽�)鞐� 鞚橅暣 鞁犼碃鞚胳潉 雽�鞁犿暣 靹滊獏霅橃棃鞀惦媹雼�.
Christopher R. Cline, directeur financier de Travere Therapeutics, a vendu 470 actions des actions ordinaires de la soci茅t茅 le 27/08/2025 au prix de 17,31 $ par action dans le cadre d'un plan 茅crit destin茅 脿 satisfaire la r猫gle 10b5-1(c). Le d茅p么t indique qu'apr猫s la transaction, M. Cline d茅tient b茅n茅fiquement 92 656 actions.
La vente a 茅t茅 ex茅cut茅e conform茅ment 脿 un plan 10b5-1 adopt茅 le 28/05/2025 et comprenait des actions suppl茅mentaires vendues pour couvrir l'obligation fiscale r茅sultant de l'acquisition de unit茅s d'actions restreintes fond茅es sur la performance qui ont acquis droit en mai 2025. Le formulaire 4 a 茅t茅 sign茅 au nom de la personne d茅clarante par un mandataire le 28/08/2025.
Christopher R. Cline, Chief Financial Officer von Travere Therapeutics, verkaufte am 27.08.2025 470 Aktien der Stammaktien des Unternehmens zum Preis von $17.31 je Aktie im Rahmen eines schriftlichen Plans zur Erf眉llung der Regel 10b5-1(c). Die Einreichung berichtet, dass Herr Cline nach der Transaktion wirtschaftlich 92.656 Aktien besitzt.
Der Verkauf erfolgte gem盲脽 einem am 28.05.2025 angenommenen 10b5-1-Plan und beinhaltete zus盲tzliche verkaufte Aktien zur Begleichung der Steuerverpflichtung, die durch das Vesting leistungsabh盲ngiger Restricted Stock Units im Mai 2025 entstand. Das Formular 4 wurde am 28.08.2025 im Namen der meldenden Person von einem Bevollm盲chtigten unterzeichnet.
FAQ
What insider transaction did Travere Therapeutics (TVTX) report for Christopher R. Cline?
Why were shares sold by Christopher Cline according to the Form 4?
How many shares does Christopher Cline beneficially own after the reported transaction?
When was the 10b5-1 plan that governed the sale adopted?
Who signed the Form 4 for the reporting person and when?
